ここが知りたい！　糖尿病診療ハンドブック　Ver.6

出版社： 中外医学社
著者：
発行日： 2024-04-15
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784498123953
電子書籍版： 2024-04-15 （6版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

最新にして最良の『糖尿病診療ハンドブック』．「合併症を起こさないように，万が一起きたら早めに専門医へ」とモットーに，一気に読めるコンパクトな書籍として大リニューアル．高齢化問題を意識した糖尿病学のアップデートをフォローするのはもちろんのこと，クリニカルイナーシャ（clinical inertia）の視点や医療サポート体制，患者支援についての内容も充実しております。糖尿病診療にかかわる全医療者にお勧めできる一冊です．

目次

  • 第1章　診断・検査
    　■1．診断・成因・病態を把握するための検査法
    　■2．合併症チェックのための検査法
    　■3．コントロール状況把握のための検査とコントロール目標

    第2章　合併症と併存症
    　(1)急性合併症と低血糖
    　■1．急性代謝障害：ケトアシドーシス，高浸透圧高血糖状態，乳酸アシドーシス
    　■2．感染症
    　■3．低血糖とシックデイ対策
    　(2) 慢性合併症
    　■1．網膜症と他の眼科疾患
    　■2．DKDとCKD
    　■3．神経障害（高齢化に伴って増える他疾患との鑑別）
    　■4．動脈硬化性疾患（動脈硬化および脳血管障害・心血管障害）
    　■5．末梢性動脈疾患と足病変
    　(3) 併存症
    　■1．がん
    　■2．糖尿病性心筋症，心不全と心房細動
    　■3．サルコペニア・フレイル
    　■4．骨粗鬆症とロコモティブシンドローム
    　■5．認知症と精神疾患
    　■6．糖尿病と口腔疾患
    　■7．糖尿病とNASH，NAFLD
    　■8．糖尿病に伴う肥満

    第3章　治療法
    　(1)治療法の基本的な考え方
    　(2) 生活療法
    　■1．食事療法
    　■2．運動療法
    　■3．禁煙
    　■4．その他の生活療法
    　(3) 薬物療法
    　■1．インスリン以外の血糖降下薬
    　■2．インスリン製剤
    　■3．糖代謝以外の治療薬

    第4章　糖尿病予防および糖尿病を有する人々をサポートするために
    医療・療養支援体制ほか
    　■1．予防医学からみた糖尿病
    　■2．患者会活動とCDEJ・CDE Local活動
    　■3．アドボカシー活動

    Column
    　●1．糖尿病と私
    　●2．糖尿病と鍼灸
    　●3．糖尿病と医療の構造
    　●4．3つの「きょとん」
    　●5．医療経済学の観点からみえる現場～糖尿病患者と向き合う医療システムを育てよう～

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 診断・検査

P.7 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
P.13 掲載の参考文献
1) Babazono T, Takahashi C, Iwamoto Y. Definition of microalbunimuria in first morning and random spot urine in diabetic patients. Diabetes Care. 2004 ; 27 : 1838-9.
 
2) 猪股茂樹, 羽田勝計, 守屋達美, 他. 糖尿病性腎症の新しい早期診断基準. 糖尿病. 2005 ; 48 : 757-9.
 
3) 日本糖尿病学会, 編. 糖尿病専門医研修ガイドブック 改訂第9版. 診断と治療社 ; 2023. p.342.
 
P.21 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
2) Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation : recommendations from the International Consensus on time in range. Diabetes Care. 2019 ; 42 : 1593-603.
PubMed
3) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン 2019. ライフサイエンス出版 ; 2019.
 
4) American Diabetes Association. 10. Cardiovascular Disease and Risk Management : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S158-90.
 
5) 日本動脈硬化学会. 動脈硬化性疾患予防ガイドライン 2022年版. 2022.
 
P.23 掲載の参考文献
1) Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970 ; 19 : 789-830.
 
2) Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 ; 28 : 103-17.
PubMed
3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 ; 352 : 837-53.
 
4) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 ; 352 : 854-65.
PubMed

第2章 合併症と併存症

P.30 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
2) Winter WE, Maclaren NK, Riley WJ, et al. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987 ; 316 : 285-91.
PubMed
3) Takada S, Hirokazu H, Yamagishi K, et al. Predictors of the onset of type 1 diabetes obtained from real-world data analysis in cancer patients treated with immune checkpoint inhibitors. Asian Pac J Cancer Prev. 2020 ; 21 : 1697-9.
PubMed
4) Dhatariya KK ; Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults-An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med. 2022 ; 39 : e14788.
PubMed
5) www.nittokyo.or.jp/modules/information/index.php?content_id=23
 
P.37 掲載の参考文献
1) Gupta S, Koirala J, Khardori R, et al. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin N Am. 2007 ; 21 : 617-38.
 
2) Senneville E, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023 : ciad527.
PubMed
3) 岩田健太郎, 他. 糖尿病患者の発熱へのアプローチ. In : IDATENセミナーテキスト編集委員会, 編. 病院内/免疫不全関連感染症診療の考え方と進め方. 医学書院 ; 2011. p.136-43.
 
4) 岩田健太郎. 糖尿病の足感染症. In : 西垂水和隆, 他編. 疾患の全体像「ゲシュタルト」をとらえる感染症の診断術. 羊土社 ; 2014. p.154-8.
 
5) Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors : a systematic review and meta-analysis. BMJ Open. 2019 ; 9 : e022577.
PubMed
6) Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England : a population-based cohort study. Lancet Diabetes Endocrinol. 2020 ; 8 : 823-33.
 
7) Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19. N Engl J Med. 2022 ; 387 : 599-610.
PubMed
P.48 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
2) Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation : recommendations from the International Consensus on time in range. Diabetes Care. 2019 ; 42 : 1593-603.
PubMed
3) American Diabetes Association. 6. Glycemic Targets : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S97-110.
PubMed
4) American Diabetes Association. 13. Older Adults : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S216-29.
PubMed
P.55 掲載の参考文献
1) 日本糖尿病眼学会診療ガイドライン委員会. 糖尿病網膜症診療ガイドライン (第1版). 日眼会誌. 2020 ; 124 : 955-81.
 
2) The diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med. 2015 ; 372 : 1193-203.
 
3) Terasaki H, Ogura Y, Kitano S, et al. Management of diabetic macular edema in Japan : a review and expert opinion. Jpn J Ophthalmol. 2018 ; 62 : 1-23.
PubMed
4) 日本糖尿病学会, 編. 特殊な病態における糖尿病治療. 糖尿病専門医研修ガイドブック 改訂第7版. 診断と治療社 ; 2017. p.388-91.
 
5) Suto C, Kato S, Muraoka K, et al. Effect of perioperative glycemic control in progression of retinopathy and maculopathy. Arch Ophthalmol. 2006 ; 124 : 38-45.
PubMed
P.67 掲載の参考文献
1) 日本腎臓学会, 編. エビデンスに基づくCKD診療ガイドライン 2023. 東京医学社 ; 2023.
 
2) Kramer H. Association between chronic kidney disease and coronary artery calcification : the Dallas Heart Study. J Am Soc Nephrol. 2005 ; 16 : 507-13.
PubMed
3) Adler AI. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003 ; 63 : 225-32.
PubMed
4) 深水圭. SGLT2阻害薬の心腎保護作用. 日腎会誌. 2021 ; 63 : 151-9.
 
5) Gorriz JL, Romera I, Cobo A, et al. Glucagon-like peptide-1 receptor agonist use in people living with type 2 diabetes mellitus and chronic kidney disease : a narrative review of the key evidence with practical considerations. Diabetes Ther. 2022 ; 13 : 389-421.
PubMed
6) 佐藤敦久. 腎疾患とアルドステロン. 日内会誌. 2008 ; 97 : 2171-8.
 
P.77 掲載の参考文献
1) 神谷英紀, 姫野龍仁, 渡会敦子, 他. 日本人2型糖尿病患者における糖尿病性対称性多発神経障害の有病率及び特徴 : JDCP研究 第10報. 糖尿病. 2023 ; 66 : 645-54.
 
2) Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy : a position statement by the American Diabetes Association. Diabetes Care. 2017 ; 40 : 136-54.
PubMed
3) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022. p.89-91.
 
4) 八木下操六, 編. 東北糖尿病合併症フォーラム, 編集協力. 診療に役立つ糖尿病神経障害の新知識. 東京医学社 ; 2008. p.19-20.
 
5) 日本糖尿病学会, 編. 糖尿病診療ガイドライン 2019. 南江堂 ; 2019. p.174-5, 334-5.
 
6) 日本性機能学会, 日本泌尿器科学会, 編. ED診療ガイドライン 第3版. RichHill Medical ; 2018. p.35-43.
 
P.84 掲載の参考文献
1) Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 ; 295 : 180-9.
PubMed
2) Marx N, Federici M, Schutt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 ; 44 : 4043-140.
PubMed
3) Saito Y, Inohara T, Kohsaka S, et al. Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction : Insights from the nationwide Japanese percutaneous coronary intervention registry. Am Heart J. 2023 ; 258 : 69-76.
PubMed
4) Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 ; 358 : 580-91.
PubMed
5) Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 ; 5 : 951-64.
PubMed
6) Tateishi K, Saito Y, Kitahara H, et al. Impact of glycemic variability on coronary and peripheral endothelial dysfunction in patients with coronary artery disease. J Cardiol. 2022 ; 79 : 65-70.
PubMed
P.92 掲載の参考文献
1) Bakker K, Schaper NC ; International Working Group on Diabetic Foot Editorial Board. The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012 ; 28 Suppl 1 : 116-8.
 
2) IWGDF Guidelines. https://iwgdfguidelines.org/guidelines-2023/
PubMed
3) 日本ペインクリニック学会, 編. 神経障害性疼痛薬物療法ガイドライン 改訂第2版. 真興交易医書出版部 ; 2016.
 
4) 日本糖尿病学会, 編. 糖尿病専門医研修ガイドブック 改訂第8版. 診断と治療社 ; 2020. p.349.
 
P.100 掲載の参考文献
1) 中村二郎, 神谷英紀, 羽田勝計, 他. -糖尿病の死因に関する委員会報告-アンケート調査による日本人糖尿病の死因-2001～2010年の10年間, 45,708名での検討-. 糖尿病. 2016 ; 59 : 667-84.
 
2) Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer : a consensus on complexity. Lancet. 2010 ; 375 : 2201-2.
 
3) 春日雅人, 植木浩二郎, 田嶼尚子, 他. 糖尿病と癌に関する委員会報告. 糖尿病. 2013 ; 56 : 374-90.
 
4) Carstensen B, Read SH, Friis S, et al. Diabetes and Cancer Research Consortium. Cancer incidence in persons with type 1 diabetes : a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia. 2016 ; 59 : 980-8.
PubMed
5) 後藤温, 能登洋, 野田光彦, 他. 糖尿病と癌に関する委員会報告 (第2報). 糖尿病. 2016 ; 59 : 174-7.
 
6) Gerstein HC. Does Insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA. 2010 ; 303 : 446-7.
 
7) Kobayashi D, Kuriyama N, Hirano K, et al. Malignancy incidences by glycemic control among diabetic patients. Endocr Connect. 2018 ; 7 : 1457-63.
PubMed
8) Saito Y, Noto H, Takahashi O, et al. Visit-to-visit Hemoglobin A1c variability is associated with later cancer development in patients with diabetes mellitus. Cancer J. 2019 ; 25 : 237-40.
PubMed
9) Mao D, Lau ESH, Wu H, et al. Risk associations of long-term HbA1c variability and obesity on cancer events and cancer-specific death in 15,286 patients with diabetes －a prospective cohort study. Lancet Reg Health West Pac. 2022 ; 18 : 100315.
PubMed
10) Hwangbo Y, Kang D, Kang M, et al. Incidence of Diabetes after cancer development : a Korean national cohort study. JAMA Oncol. 2018 ; 4 : 1099-105.
PubMed
P.108 掲載の参考文献
1) Dauriz M, Mantovani A, Bonapace S, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure : a meta-analysis. Diabetes Care. 2017 ; 40 ; 1597-605.
PubMed
2) Dandamudi S, Slusser J, Mahoney DW, et al. The prevalence of diabetic cardiomyopathy : a population based study in olmsted county, Minnesota. J Card Fail. 2014 ; 20 : 304-9.
PubMed
3) American Diabetes Association. 10. Cardiovascular Disease and Risk Management : Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 ; 44 (Suppl 1) : S125-50.
 
4) Sanganalmath SK, Dubey S, Veeranki S, et al. The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy. Cardiovasc Diabetol. 2023 ; 22 : 37.
 
5) Kunadian V, Chieffo A, Camici PG, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020 ; 41 : 3504-20.
 
6) Abudureyimu M, Luo X, Wang X, et al. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus : from pathophysiology to therapeutics. Mol. Cell Biol. 2022 ; 14 : mjac028.
PubMed
7) Arnold JR, Kanagala P, Budgeon CA, et al. Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction. JACC Cardiovas Imaging. 2022 ; 15 : 1001-101.
 
8) Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009 ; 73 : 1893-900.
PubMed
9) Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 ; 381 : 1609-20.
PubMed
10) Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction : a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023 ; 44 : 2982-93.
 
11) Castellana M, Procino F, Sardone R, et al. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population : a systematic review and met-analysis. Cardiovasc Diabetol. 2020 ; 19 : 87.
 
12) Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure : a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 ; 400 : 757-67.
PubMed
13) Groenewegen A, Zwartkruis VW, Cekic B, et al. Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovasc Diabetol. 2021 ; 20 : 123.
PubMed
14) Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gene Int Med. 2010 ; 25 : 853-8.
 
15) Marrouche NF, Brachmann J, Andersen D, et al. Catheter ablation for arterial fibrillation with heart failure. N Engl J Med. 2018 ; 378 : 417-20.
 
16) Chao TF, Suenari K, Chang SL, et al. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol. 2010 ; 106 : 1615-20.
PubMed
17) Li WJ, Chen XQ, Xu LL, et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes : a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020 ; 19 ; 130.
 
P.117 掲載の参考文献
1) Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 2010 ; 210 : 901-8.
PubMed
2) Satake S, Arai H. The revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria). Geriatr Gerontol Int. 2020 ; 20 : 992-3.
PubMed
3) Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity : ESPEN and EASO consensus statement. Clin Nutr. 2022 ; 41 : 990-1000.
PubMed
4) Hirata Y, Nomura K, Senga Y, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. vol. 4 : 2019 ; e124952, 124952.
 
5) Sasako T, Umehara T, Soeda K, et al. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. Nat Commun. 2022 ; 13 : 5655.
PubMed
6) O'Neill BT, Bhardwaj G, Penniman CM, et al. FoxO transcription factors are critical regulators of diabetes-related muscle atrophy. Diabetes. 2019 ; 68 : 556-70.
PubMed
7) Bouchi R, Fukuda T, Takeuchi T, et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int. 2017 ; 101 : 1-8.
PubMed
8) Koshizaka M, Ishikawa K, Ishibashi R, et al. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus : Subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig. 2021 ; 12 : 200-6.
 
9) Yabe D, Shiki K, Homma G, et al. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>- 65 years) with type 2 diabetes : a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab. 2023 ; 25 : 3538-48.
PubMed
10) Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011 ; 34 : 2381-6.
PubMed
P.126 掲載の参考文献
1) Napoli N, Chandran M, Pierroz DD, et al ; IOF Bone and Diabetes Working Group. Mechanism of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017 ; 13 : 208-19.
 
2) Hofbauer LC, Busse B, Eastell R, et al. Bone fragility in diabetes : novel concepts and clinical implications. Lancet Diabetes Endocrinol. 2022 ; 10 : 207-20.
PubMed
3) Leanza G, Maddaloni E, Pitocco D, et al. Risk factors for fragility fractures in type 1 diabetes. Bone. 2019 ; 125 : 194-9.
 
4) Saito M, Marumo K. Collagen cross-links as a determinant of bone quality : a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010 ; 21 : 195-214.
PubMed
5) Oei L, Zillikens, MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control : the Rotterdam Study. Diabetes Care. 2013 ; 36 : 1619-28.
PubMed
6) Li CI, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes : a competing risk analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res. 2015 ; 30 : 1338-46.
PubMed
7) Erythropoulou-Kaltsidou A, Polychronopoulos G, Tziomalos K. Sodium-glucose co-transporter 2 inhibitors and fracture risk. Diabetes Ther. 2020 ; 11 : 7-14.
PubMed
8) Jackuliak P, Kuzma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res. 2019 ; 68 (Suppl 2) : S107-20.
 
9) 日本骨粗鬆症学会生活習慣病における骨折リスク評価委員会, 編. 生活習慣病骨折リスクに関する診療ガイド 2019年版. 日本骨粗鬆症学会 ; 2019.
 
10) Ohira M, Suzuki S, Yoshida T, et al. Fracture risk assessment tool may not indicate bone fragility in woman with type 2 diabetes. Am J Med Sci. 2020 ; 360 : 552-9.
PubMed
11) Grygorieva N, Musiienko A, Zaverukha N, et al. Bone mineral density and probability of osteoporotic fracture in women with type ii diabetes mellitus. Wiad Lek. 2020 ; 75 : 2920-5.
 
12) Sheu A, Greenfield JR, White CP, et al. Assessment and treatment of osteoporosis and fracture in type 2 diabetes. Trends Endocrinol Metab. 2022 ; 33 : 333-44.
PubMed
13) Asakura R, Miyatake N, Mochimasu KD, et al. Comparison of health-related quality of life between type 2 diabetic patients with and without locomotive syndrome. Environ Health Prev Med. 2016 ; 21 : 356-60.
PubMed
14) Handa M, Kato S, Sakurai G, et al. The prevalence of locomotive syndrome and its associated factors in patients with Type 2 diabetes mellitus. Mod Rheumatol. 2023 ; 33 : 422-7.
PubMed
P.135 掲載の参考文献
1) Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia : The Rotterdam Study. Neurology. 1999 ; 53 : 1937-42.
PubMed
2) Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community : the Hisayama study. Neurology. 2011 ; 77 : 1126-34.
PubMed
3) Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism : implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013 ; 108 : 21-43.
 
4) Moreno-Gonzalez I, Edwards Iii G, Salvadores N, et al. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry. 2017 ; 22 : 1327-34.
PubMed
5) Kim E, Je Y. Fish consumption and the risk of dementia : systematic review and meta-analysis of prospective studies. Psychiatry Res. 2022 ; 317 : 114889.
PubMed
6) Yanai H, Hamasaki H, Katsuyama H, et al. Effects of intake of fish or fish oils on the development of diabetes. J Clin Med Res. 2015 ; 7 : 8-12.
 
7) Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan : a meta-analysis. Diabetes Care. 2008 ; 31 : 2383-90.
PubMed
8) American Psychiatric Association. 日本精神神経学会, 日本語版用語監修. 高橋三郎, 大野裕, 監訳. DSM-5-TR 精神疾患の診断・統計マニュアル. 医学書院 ; 2023.
 
9) Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia : a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015 ; 132 : 144-57.
PubMed
10) Gorczynski P, Firth J, Stubbs B, et al. Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis. Psychiatry Res. 2017 ; 250 : 17-24.
PubMed
11) 七澤英毅. 抗精神病薬と糖尿病. 医療. 2019 ; 73 : 496-9.
Medical*Online
P.144 掲載の参考文献
1) 日本歯周病学会, 編. 糖尿病患者に対する歯周治療のガイドライン 2022. 医歯薬出版 ; 2022.
 
2) Loe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993 ; 16 : 329-34.
PubMed
3) Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes : a two-way relationship. Diabetologia. 2012 ; 55 : 21-31.
PubMed
4) Simpson TC, Clarkson JE, Worthington HV, et al. Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Cochrane Database of Syst Rev. 2022 ; 4 : CD004714.
PubMed
5) 日本歯周病学会, 編. 糖尿病患者に対する歯周治療ガイドライン 改訂第3版. 医歯薬出版 ; 2023. p.8-32.
 
6) Harada K, Morino K, Ishikawa M, et al. Glycemic control and number of natural teeth : analysis of cross-sectional Japanese employment-based dental insurance claims and medical check-up data. Diabetology Int. 2022 ; 13 : 244-52.
 
7) 日本糖尿病学会, 編. 糖尿病診療ガイドライン 2019. 南江堂 ; 2019. p.219-28.
 
P.156 掲載の参考文献
1) Rinella M, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 24 : S0168-8278 (23) 00418-X.
 
2) 日本肝臓学会, 編. NASH・NAFLDの診療ガイド 2021. 文光堂 : 2021.
 
3) 日本消化器病学会, 日本肝臓学会, 編. NAFLD/NASH診療ガイドライン 2020 改訂第2版. 南江堂 ; 2020.
 
4) Ampuero J. General overview about the current management of nonalcoholic fatty liver disease. Clin Drug Invest. 2022 ; 42 (Suppl 1) : S39-45.
 
5) Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : A systematic review and metaanalysis. J Hepatology. 2019 ; 71 : 793-801.
 
6) Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology no nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 ; 64 : 73-84.
PubMed
7) Musso G, Gambino R, Cassader M, et al. Meta-analysis : natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011 ; 43 : 617-49.
PubMed
8) Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese of lean non-alcoholic fatty liver disease : a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 ; 5 : 739-52.
PubMed
9) Eslam N, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement. J Hepatol. 2020 ; 73 : 202-9.
 
10) 川口巧. 脂肪肝の新概念 : MAFLD (Metabolic Dysfunction Associated Fatty Liver Disease). 糖尿病. 2023 ; 66 : 464-7.
 
11) 春日正人, 植木浩二郎, 田嶼尚子, 他. 糖尿病と癌に関する委員会報告. 糖尿病. 2013 ; 56 : 374-90.
 
12) Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease : an updated meta-analysis. Gut. 2022 ; 71 : 156-62.
PubMed
P.166 掲載の参考文献
1) Onozaki A, Nagayama D, Azuma N, et al. Relation of maximum lifetime body mass index with age at hemodialysis initiation and vascular complications in Japan. Obes Facts. 2021 ; 14 : 550-8.
PubMed
2) 小山朝一, 齋木厚人, 白井厚治, 他. ロールシャッハ・テストを用いた肥満症患者の性格特性分析ハイラムダスタイルについて. 肥満研究. 2009 ; 15 : 39-44.
 
3) Shirai K, Saiki A, Oikawa S, et al. The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients-multicenter trial. Obes Res Clin Pract. 2013 ; 7 : e43-54.
PubMed
4) Saiki A, Yamaguchi T, Sasaki A, et al. Background characteristics and diabetes remission after laparoscopic sleeve gastrectomy in Japanese patients with type 2 diabetes stratified by BMI : subgroup analysis of J-SMART. Diabetol Int. 2021 ; 12 : 303-12.
PubMed
5) Saiki A, Yamaguchi T, Tanaka S, et al. Background characteristics and postoperative outcomes of insufficient weight loss after laparoscopic sleeve gastrectomy in Japanese patients. Ann Gastroenterol Surg. 2019 ; 26 ; 3 : 638-47.
PubMed
6) Watanabe Y, Yamaguchi T, Nagayama D, et al. Factors associated with relapse of type 2 diabetes mellitus after laparoscopic sleeve gastrectomy in Japanese subjects : a subgroup analysis of J-SMART study. Obes Facts. 2023 ; 16 : 119-30.
PubMed
7) Saiki A, Kanai R, Nakamura S, et al. Impact of mental health background and nutrition intake on medium-term weight loss in Japanese patients undergoing laparoscopic sleeve gastrectomy. Obes Facts. 2020 ; 13 : 371-83.
PubMed
P.169 掲載の参考文献
1) 後藤由夫. 糖尿病と東洋医学. 日本東洋医学雑誌. 1993 ; 44 : 145-58.
 
2) Cho E, Kim W. Effect of acupuncture on diabetic neuropathy : a narrative review. Int J Mol Sci. 2021 ; 22 : 8575.
 
3) Chen C, Liu J, Sun M, et al. Acupuncture for type 2 diabetes mellitus : a systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2019 ; 36 : 100-12.
 
4) 東洋療法学校協会, 編. はりきゅう理論 <第3版>. 医道の日本社 ; 2021.
 
5) 坂本歩, 監修. 鍼灸安全対策ガイドライン. 医歯薬出版 ; 2020.
 
6) 矢野忠, 編. 図解鍼灸療法技術ガイド II. 文光堂 ; 2012.
 

第3章 治療法

P.172 掲載の参考文献
1) American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S140-57.
PubMed
2) 日本糖尿病学会, 編. 糖尿尿治療の目標. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022. p.31-2.
 
P.179 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病診療ガイドライン 2019. 南江堂 ; 2019.
 
2) 日本老年医学会, 日本糖尿病学会, 編. 高齢者糖尿病診療ガイドライン 2023. 南江堂 ; 2023.
 
3) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
4) ESPEN (European Society for Clinical Nutrition and Metabolism : 欧州臨床栄養代謝学会).
 
5) 日本糖尿病学会, 編. 糖尿病食事療法のための食品交換表 第7版. 文光堂 ; 2013.
 
6) Kuwata H, Iwasaki M, Shimizu S, et al. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes : a randomised, controlled crossover, exploratory trial. Diabetologia. 2016 ; 59 : 453-61.
PubMed
7) Jakubowicz D, Wainstein J, Ahren B, et al. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients : a randomised clinical trial. Diabetologia. 2015 ; 58 : 912-9.
PubMed
8) 日本糖尿病学会, 編. カーボカウントの手びき「糖尿病食事療法のための食品交換表」準拠. 文光堂 ; 2017.
 
P.187 掲載の参考文献
1) Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997 ; 12 : 38-48.
PubMed
2) 日本老年医学会, 日本糖尿病学会, 編. 高齢者糖尿病治療診療ガイドライン 2023. 南江堂 ; 2023.
 
P.192 掲載の参考文献
1) Erlich DR, Slawson DC, Shaughnessy AF. "Lending a Hand" to Patients with type 2 diabetes : a simple way to communicate treatment goals. Am Fam Physician. 2014 ; 89 : 256, 258.
 
2) Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes. A systematic review and meta-analysis. JAMA. 2007 ; 298 : 2654-64.
PubMed
3) Katayama S, Moriya T, Tanaka S, et al. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011 ; 54 : 1025-31.
PubMed
4) Sakata R, McGale P, Grant EJ, et al. Impact of smoking on mortality and life expectancy in Japanese smokers : a prospective cohort study. BMJ. 2012 ; 345 : e7093.
PubMed
5) Hu Y, Zong G, Liu G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. N Engl J Med. 2018 ; 379 : 623-32.
PubMed
P.200 掲載の参考文献
1) Whitaker KM, Lutsey PL, Ogilvie RP, et al. Associations between polysomnography and actigraphy-based sleep indices and glycemic ontrol among those with and without type 2 diabetes : the Multi-Ethnic Study of Atherosclerosis. Sleep. 2018 ; 41 : 11.
 
2) Jakubowicz D, Wainstein J, Ahren B, et al. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients : a randomised clinical trial. Diabetologia. 2015 ; 58 : 912-9.
PubMed
P.213 掲載の参考文献
1) American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S140-57.
PubMed
2) 坊内良太郎, 近藤龍也, 太田康晴, 他. 2型糖尿病の薬物療法のアルゴリズム. 糖尿病. 2023 ; 66 : 715-33.
 
3) 日本糖尿病学会, 編. 糖尿病治療ガイド 2022-2023. 文光堂 ; 2022.
 
4) 日本糖尿病・生活習慣病ヒューマン・データ学会. 糖尿病標準診療マニュアル 2023.
 
P.224 掲載の参考文献
1) Nauck MA, Meier JJ. Incretin hormones : their role in health and disease. Diabetes Obes Metab. 2018 ; 20 Suppl 1 : 5-21.
 
2) 内田大学. DPP-4阻害薬 週1回製剤の効果と有効な投与法. 糖尿病診療マスター. 2017 ; 15 : 26-31.
 
3) Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 ; 7 : 776-85.
PubMed
4) 坊内良太郎, 近藤龍也, 太田康晴, 他. 2型糖尿病の薬物療法のアルゴリズム. 糖尿病. 2022 ; 65 : 419-34.
 
5) Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono) : a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 ; 10 : 623-33.
 
P.237 掲載の参考文献
1) Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy : a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015 ; 38 : 376-83.
PubMed
2) Garg SK, Peters AL, Buse JB, et al. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors : A STICH Protocol. Diabetes Technol Ther. 2018 ; 20 : 571-5.
PubMed
3) Zinman B, Wanner C, Lachin JM, et al ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 ; 373 : 2117-28.
PubMed
4) Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 ; 393 (10166) : 31-9.
PubMed
5) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 ; 383 : 1436-46.
PubMed
6) Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022 ; 43 : 416-26.
PubMed
7) Monteiro P, Bergenstal RM, Toural E, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing. 2019 ; 48 : 859-66.
 
8) Kaku K, Isaka H, Sakatani T, et al. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus : A randomized, double-blind, phase 3 trial. Diabetes Obes Metab. 2019 ; 21 : 2284-93.
 
P.248 掲載の参考文献
1) Foretz M, Guigas B, Viollet B. Metformin : update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023 ; 19 : 460-76.
 
2) ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Care in Diabetes-2023. Diabetes Care. 2023 ; 46 : S140-57.
PubMed
3) Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359 : 1577-89.
PubMed
4) Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010 ; 170 : 1892-9.
PubMed
5) Hallakou-Bozec S, Vial G, Kergoat M, et al. Mechanism of action of Imeglimin : A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 ; 23 : 664-73.
PubMed
6) Singh AK, Singh A, Singh R, et al. Efficacy and safety of imeglimin in type 2 diabetes : A systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metab Syndr. 2023 ; 17 : 102710.
PubMed
7) Hagi K, Kochi K, Watada H, et al. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus : a post-hoc analysis of two randomized, placebo-controlled trials. J Diabetes Investig. 2023 ; 14 : 1101-9.
PubMed
P.257 掲載の参考文献
1) ADVANCE Collaborative Group ; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358 : 2560-72.
 
2) Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced GLP-1 and reduced GIP responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med. 2009 ; 26 : 187-8.
 
3) Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIODDM trial. JAMA. 2003 ; 290 : 486-94.
PubMed
4) Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Voglibose Ph-3 Study Group. Lancet. 2009 ; 373 : 1607-14.
 
5) DeFronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study : pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011 ; 364 : 1104-15.
PubMed
6) Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet. 2005 ; 366 : 1279-89.
PubMed
7) Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015 ; 314 : 265-77.
PubMed
P.267 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病診療ガイドライン 2019. 南江堂 ; 2019. p.94-5.
 
P.275 掲載の参考文献
1) 島田朗, 川崎英二, 阿比留教生, 他. 緩徐進行1型糖尿病の診断基準 (2023) -1型糖尿病における新病態の探索的検討委員会報告-. 糖尿病. 2023 ; 66 : 587-91.
 
2) 島田朗, 川崎英二, 阿比留教生, 他. 緩徐進行1型糖尿病疑い例への治療介入に関するステートメント-1型糖尿病における新病態の探索的検討委員会-. 糖尿病. 2023 ; 66 : 807-14.
 
P.282 掲載の参考文献
1) Meece J. Basal insulin intensification in patients with type 2 diabetes : a review. Diabetes Ther. 2018 ; 9 : 877-90.
PubMed
2) Juris J, Michael A. Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? Diabetes. 2010 ; 59 : 1117-25.
 
P.292 掲載の参考文献
1) Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376 : 1670-81.
PubMed
2) Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 ; 372 : 2387-97.
PubMed
3) Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 ; 376 : 1713-22.
PubMed
4) Noguchi T, Kobayashi J, Yagi K, et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus : results from a crossover study. Atherosclerosis. 2011 ; 217 : 165-70.
PubMed
5) Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet. 2007 ; 369 : 1090-8.
PubMed
6) Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023 ; 81 : 1553-64.
PubMed
7) Minamizuka T, Kobayashi J, Tada H, et al. A Japanese case of familial hypercholesterolemia with a protein-truncating variant in LDLR and PCSK9 variant without significant atherosclerosis but showing remarkable achilles tendon thickening. Internal Medicine. in press.
 
P.302 掲載の参考文献
1) American Diabetes Association. Microvascular complications and foot care : Standard Medical Care in Diabetes 2016. Diabetes Care. 2016 ; 39 : S72-80.
 
2) American Diabetes Association : Standard Medical Care in Diabetes 2010. Diabetes Care. 2010 ; 30 : S4-10.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン 2019. ライフサイエンス出版 ; 2019. p.124-6.
 
4) Kunimura A, Himuro N, Fujiyoshi A, et al. The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes : a systematic review and meta-analysis of randomized controlled trials. Hypertens Res. 2019 ; 42 : 669-80.
PubMed

第4章 糖尿病予防および糖尿病を有する人々をサポートするために

P.313 掲載の参考文献
1) 日本糖尿病学会, 編. 低血糖症. 糖尿病専門医研修ガイドブック 改訂第7版. 診断と治療社 ; 2017. p.421-30.
 
2) Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 ; 346 : 393-403.
 
3) Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019 ; 381 : 603-13.
PubMed
4) Ramirez V, Gonzalez-Palacios P, Baca MA, et al. Effect of exposure to endocrine disrupting chemicals in obesity and neurodevelopment : The genetic and microbiota link. Sci Total Environ. 2022 ; 852 : 158219.
 
5) Gluckman PD, Hanson MA. Living with the past : evolution, development, and patterns of disease. Science. 2004 ; 305 : 1733-6.
PubMed
6) Richardson AS, Ghosh-Dastidar M, Beckman R, et al. Can the introduction of a full-service supermarket in a food desert improve residents' economic status and health? Ann Epidemiol. 2017 ; 27 : 771-6.
 
P.319 掲載の参考文献
1) Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label randomized controlled trial. Lancet Diabetes Endocrinol. 2017 ; 5 : 951-64.
PubMed
2) 岡崎由紀子. J-DOIT3における生活習慣介入-チーム医療の視点から. 糖尿病プラクティス. 2018 ; 35 : 147-50.
 
3) アメリカ糖尿病教育者協会, 編. 三村悟郎, 福満昭二, 監訳. 糖尿病教育・健康管理専門家のためのコアカリキュラム. 糖尿病研究・治療・教育振興会 ; 1992.
 
P.326 掲載の参考文献
1) 南昌江. 1型糖尿病のスティグマ. 糖尿病. 2023 ; 66 : 234-6.
 
2) 加藤明日香. 2型糖尿病と「スティグマ」. 総合診療. 2023 ; 33 : 329-31.
 
3) 田中永昭. どうして糖尿病患者さんのアドボカシーが注目されているのか. 日糖尿教看会誌. 2022 ; 26 : 85-9.
 
4) 石井均. 2型糖尿病のスティグマー心理社会的視点から. 糖尿病. 2023 ; 66 : 237-9.
 
5) 加藤光敏. 糖尿病の "スティグマ" と "アドボカシー" って何だろう? 診療研究. 2022 ; 583 : 44-6.
 
P.328 掲載の参考文献
1) 国際糖尿病連合 (IDF) 糖尿病アトラス 2019 第9版. International Diabetes Federation (IDF) Diabetes Atlas 9th Edition (2019). New IDF figures show continued increase in diabetes across the globe, reiterating the need for urgent action. https://www.idf.org/news/94:new-idf-figures-show-continued-increase-in-diabetes-across-the-globe,-reiterating-the-need-for-urgent-action.html
 
2) 稲田扇, 西村周三, 清野裕, 他. 2型糖尿病における外来医療費の研究. ～医療改革が糖尿病科に与える影響. 糖尿病. 2005 ; 48 : 677-84.
 
3) 稲田扇, 西村周三, 松島宗弘, 他. 人工透析の直接医療費とQOLに関する研究～透析非糖尿病, 透析糖尿病および非透析糖尿病患者間の比較. 糖尿病. 2007 : 50 : 1-8.
 
4) 稲田扇. 医療経済と保険適応「2型糖尿病の医療費」. 肥満と糖尿病. 2009 ; 8 : 672-5.
 
5) 稲田扇. 医療経済～2型糖尿病の医療費とQOL. 日本女性科学者の会学術誌. 2011 ; 11 : 36-41.
 
6) 稲田扇, 稲田明理. 糖尿病の医療と医療経済～医療制度による医療費決定の仕組みと日本の糖尿病医療の課題. 日本女性科学者の会学術誌. 2020 ; 20 : 33-40.
 

書評

最近チェックした商品履歴

Loading...